Global stocks slumped as Asia and Europe saw scattered losses, the dollar dropped to a five-week low, the euro retreated, and gold climbed to levels not seen since April.Global stocks slumped as Asia and Europe saw scattered losses, the dollar dropped to a five-week low, the euro retreated, and gold climbed to levels not seen since April.

Global stocks slump as dollar hits five-week low and gold climbs

Global stocks slumped Monday as Asia and Europe saw scattered losses, the dollar dropped to a five-week low, the euro retreated, and gold climbed to levels not seen since April.

In Asia, traders reacted to the mixed batch of factory data from China. A private gauge of manufacturing activity (the RatingDog index) came in at 50.5 for August, barely signaling growth.

That was a slight improvement from July’s 49.5. But the government’s own official PMI, released a day earlier, stayed stuck under 50 at 49.4, up marginally from the previous 49.3. Both readings showed China’s factory sector is far from recovering in full.

At the Shanghai Cooperation Organization’s two-day security summit, Chinese President Xi Jinping urged member nations to “strengthen cooperation in artificial intelligence.” Speaking at the opening session, Xi said the group should reject what he described as a “Cold War mentality.”

Hang Seng rallies, but Japan and Korea slide

The Hang Seng index in Hong Kong closed 2.17% higher at 25,617.42, led by a strong showing from Alibaba Group, which jumped 18.58%. CSPC Pharmaceutical Group surged 9.53% and WuXi Biologics rose 8.37%. On the mainland, the CSI 300 gained 0.6% and ended the session at 4,523.71, despite volatile trade.

Japan’s Nikkei 225 slid 1.24% to 42,188.79, weighed down by semiconductor losses. Advantest lost 7.92%, Disco Corporation dropped 7.71%, and Socionext fell 6.32%. The broader Topix also declined 0.39%, finishing at 3,063.19.

Over in South Korea, the Kospi lost 1.35%, ending at 3,142.93, while the Kosdaq slipped 1.49% to 785. Australia wasn’t spared either. The S&P/ASX 200 dropped 0.51%, closing at 8,927.70. Only India bucked the trend. The Nifty 50 gained 0.66% and the BSE Sensex climbed 0.6% as of early afternoon.

Trump tariffs overturned as European indexes hold steady

In the U.S., Trump took a legal hit on Friday after a Federal Appeals Court ruled that his 2023 “reciprocal tariffs” breached presidential authority. The court declared the sweeping levies on imports from dozens of nations unlawful.

Wall Street had ended last week in the red. The S&P 500 fell 0.64% to 6,460.26 but still locked in its fourth straight monthly gain. The Nasdaq Composite dropped 1.15% to 21,455.55, and the Dow Jones gave up 92.02 points to close at 45,544.88.

All three indexes responded to new inflation readings that showed price pressures remain stubborn. U.S. markets stayed closed Monday for Labor Day.

In Europe, stocks stayed mostly flat. Spain’s IBEX 35 slipped 0.25% to 14,898.5. The UK’s FTSE 100 added 0.27%, finishing at 9,212.53. Germany’s DAX rose 0.53% to 24,028.09, France’s CAC 40 added 0.44% to 7,737.67, and the STOXX600 ended up 0.39% at 552.31.

Currency markets saw the dollar continue its slide. The ICE U.S. Dollar Index dropped to 97.618, losing 0.16% on the day and notching a 2.2% monthly fall. The euro traded at 1.172, up 0.334%, while the pound sterling gained 0.18% to hit 1.353.

The euro/yen moved to 172.4, and the euro/sterling pair reached 0.866. The dollar/yen cross stayed flat at 147.00 after August’s 2.5% drop.

Meanwhile, the yuan held steady near a 10-month high at 7.1326 per dollar. Central bank support and a strong stock market inside China helped stabilize the currency, even though the wider economy is still wobbling. The People’s Bank of China continued setting firm daily fixings, giving investors a signal that it won’t let the yuan slide further for now.

In metals, gold rallied hard. Spot prices hit $3,486.86 per ounce, rising 1.2% as of 0641 GMT. Futures for December delivery moved up 1.1% to $3,554.60. The gains came as traders placed bigger bets on a Fed rate cut this month. Silver broke $40 for the first time since 2011, hitting $40.56. Platinum jumped 1.5% to $1,384.68. Palladium gained 0.8%, reaching $1,118.06.

If you're reading this, you’re already ahead. Stay there with our newsletter.

Market Opportunity
Notcoin Logo
Notcoin Price(NOT)
$0,0006459
$0,0006459$0,0006459
+2,16%
USD
Notcoin (NOT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23